The European Commission has proposed to the European Union (EU)Member States to purchase an additional 200 million doses of the COVID-19 vaccine produced by BioNTech and Pfizer, with the option to acquire another 100 million doses. According to a press statement, “ This would enable the EU to purchase up to 600 million doses of this vaccine, which is already being used across the EU.
The additional doses will be delivered starting in the second quarter of 2021. The EU has acquired a broad portfolio of vaccines with different technologies. It has secured up to 2.3 billion doses from the most promising vaccine candidates for Europe and its neighbourhood. In addition to the BioNTech-Pfizer vaccine, a second vaccine, produced by Moderna, was authorised on 6 January 2021. Other vaccines are expected to be approved soon”.
As per a Statement by President von der Leyen on additional doses of BioNTech-Pfizer vaccine, “ we have right now access to 300 million doses of the BioNTech-Pfizer vaccine. Now the good news: We have now agreed with BioNTech-Pfizer to extend this contract. With the new agreement, we could purchase a total of up to an additional 300 million doses of the BioNTech-Pfizer vaccine – in other words, this will allow us to double the amount of doses of BioNTech-Pfizer.
And I am particularly pleased that 75 million doses of this order will already be available as of quarter two onwards. The rest would then be delivered in the third and in the fourth quarter of 2021”.